Priority Review Weirdness: Tropical Voucher Sells For More; Owner Says It’s Worth Less
Executive Summary
Knight Therapeutics says a rare pediatric disease voucher is more valuable than its tropical disease voucher despite the sale price.
You may also be interested in...
Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher
Priority review ticket might be used on Type 2 diabetes combo LixiLan, expected to be filed later this year.
Pricing, Pediatrics, Pot: 21st Century Cures Amendments
Committee members didn’t even vote on any amendments besides the manager’s package, but proposals floated and withdrawn offer glimpse at potential fights to come.
21st Century Cures Now A Partially Funded Mandate For FDA
Amended bill passes full House Energy and Commerce Committee unanimously with another $550 million in appropriations for FDA.